Skip to content

Medical emergency? What to do

F.T.C. Criticizes Agreements That Delay Generic Drugs

3-RXPublished September 1, 20112 min read

Key points

  • Some drug makers are using an indirect method to delay competition from low-cost generic products by promising not to introduce their own generic versions if a potential competitor delays its entry into the market, the Federal Trade Commission said in a report on Wednesday.
  • The F.T.C. says they are illegal sweetheart deals that cost consumers $3.5 billion a year.
  • The Generic Pharmaceutical Association called the study part of a “misguided policy to ban pro-consumer patent litigation settlements.
  • But it was disturbing, he said, how often agreements not to compete have been used to compensate generic firms for delaying entry to the market.

Some drug makers are using an indirect method to delay competition from low-cost generic products by promising not to introduce their own generic versions if a potential competitor delays its entry into the market, the Federal Trade Commission said in a report on Wednesday.

Until lately, the so-called pay-for-delay cases have focused mostly on cash payments by drug companies to settle patent litigation with generic competitors in return for concessions on when to enter the market. These new agreements add a twist to the patent settlements.

The industry contends they are legal business decisions.

The F.T.C. says they are illegal sweetheart deals that cost consumers $3.5 billion a year.

“Win-win for the companies, but lose-lose for consumers,” the F.T.C. chairman, Jon Leibowitz, said in an interview on Wednesday after the agency released a 270-page study on so-called brand-name generics.

The Generic Pharmaceutical Association called the study part of a “misguided policy to ban pro-consumer patent litigation settlements.” The system works, the industry trade group said, noting that 17 of 23 expected generic drug introductions this year, like Lipitor and Plavix, will be the result of patent settlements.

The F.T.C. report, based in part on industry documents, found that generic drugs made by the original company, when competing against a truly generic drug in the first 180 days of competition, reduced overall prices by 4 percent to 8 percent.

That was unsurprising, Mr. Leibowitz said. But it was disturbing, he said, how often agreements not to compete have been used to compensate generic firms for delaying entry to the market.

In the 12 months ended Sept. 30, 2010, 15 drug patent settlements combined a promise not to market a brand-name generic drug with a generic company’s agreement to delay its entry to market, the report said.

“Instead of saying, ‘Here’s $200 million, go away,’ they’re saying they could penalize them $200 million, but they won’t, so go away,” Mr. Leibowitz said.

The Pharmaceutical Research and Manufacturers of America, a Washington trade group, said the report proved that brand-name generics help reduce prices.

“However, it is unfortunate that the F.T.C. used this potentially valuable report on the benefits to patients of authorized generics to further its attack on patent settlements,” the group’s senior vice president, Matthew D. Bennett, said in a statement.

###

By DUFF WILSON

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.